Nkarta, Inc.
NKTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787400
No open-market purchases or sales by Nkarta, Inc. insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $167.9M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +12 vs. previous quarter
- 135
- 13F valueReported value at the end of Q2 2026
- $167.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NKTX, Q2 2026
No superinvestor reported holding NKTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Nkarta, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Hastings Paul JChief Executive Officer | SSale | −1.78K | $2.71 | −$4.81K | −0.5%390.2K after | |
| Jan 20, 2026 (view filing) | Jan 15 | 5 days | Hastings Paul JChief Executive Officer | SSale | −26.0K | $2.07 | −$53.9K | −6.3%390.0K after | |
| Jan 20, 2026 (view filing) | Jan 15 | 5 days | Mahmood NadirPresident | SSale | −5.65K | $2.07 | −$11.7K | −3.3%167.7K after | |
| Jun 20, 2025 (view filing) | Jun 18 | 2 days | Hastings Paul JChief Executive Officer | SSale | −1.79K | $1.79 | −$3.20K | −0.6%320.1K after | |
| Jan 17, 2025 (view filing) | Jan 15 | 2 days | Shook DavidSee Remarks | SSale | −8.64K | $2.20 | −$19.0K | −4.3%191.0K after | |
| Jan 17, 2025 (view filing) | Jan 15 | 2 days | Levin AlyssaSee Remarks | SSale | −5.84K | $2.20 | −$12.8K | −5.4%102.7K after | |
| Jan 17, 2025 (view filing) | Jan 15 | 2 days | Brandenberger RalphChief Technical Officer | SSale | −7.45K | $2.20 | −$16.4K | −5.6%124.8K after | |
| Jan 17, 2025 (view filing) | Jan 15 | 2 days | Hastings Paul JChief Executive Officer | SSale | −17.4K | $2.20 | −$38.2K | −5.2%319.9K after | |
| Jan 17, 2025 (view filing) | Jan 15 | 2 days | Hager Alicia J.Chief Legal Officer | SSale | −9.58K | $2.20 | −$21.1K | −6.1%146.7K after | |
| Jul 18, 2024 (view filing) | Jul 16 | 2 days | Hager Alicia J.Chief Legal Officer | SSale | −3.40K | $8.00 | −$27.2K | −3.2%103.8K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Nkarta, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 10,805,129 | $30.6M | 0.27% | 00.0% | Unchanged |
| BlackRock, Inc. | 6,300,212 | $17.8M | 0.00% | +1,791,739+39.7% | Added |
| NEA Management Company, LLC | 3,568,781 | $10.1M | 0.64% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 3,507,666 | $9.93M | 0.82% | 00.0% | Unchanged |
| Sr One Capital Management, LP | 3,333,333 | $9.43M | 0.91% | 00.0% | Unchanged |
| GSK plc | 3,150,732 | $8.92M | 1.48% | 00.0% | Unchanged |
| Monaco Asset Management SAM | 2,373,400 | $6.72M | 2.50% | −148,532−5.9% | Reduced |
| Vanguard Capital Management LLC | 2,226,415 | $6.30M | 0.00% | +214,994+10.7% | Added |
| Citadel Advisors LLC | 2,174,745 | $6.15M | 0.00% | +390,751+21.9% | Added |
| Two Sigma Investments, LP | 1,873,293 | $5.30M | 0.00% | −174,083−8.5% | Reduced |